As with many diseases, our knowledge of type 2 diabetes mellitus is increasing through research. Recent developments include the use of new treatments and guidelines in clinical practice. There has been an update to the IDF guidelines concerning glucagon-like peptide-1 agonist (GLP-1 agonists), dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitors) are now used in the treatment of diabetes, and sodium glucose co-transporter 2 (SGLT-2) inhibitors are being investigated for this use.
The Diabetes Knowledge Centre aims to provide endocrinologists and other healthcare professionals with the latest information in the area of type 2 diabetes mellitus. Containing information on complications, HbA1C levels, incretins, screening and diagnosis, as well as treatment and management options, this interactive resource is essential viewing for endocrinologists and other healthcare professionals with an interest in diabetes.
The Men’s Health Knowledge Centre is a resource for healthcare professionals contains a latest updates section with monthly editorials of recently published articles in the area of hypogonadism (low testosterone), and the effect this hormone deficiency has on has on hypogonal men. This clear and concise information concerning this endocrine disorder makes this resource essential regular viewing for endocrinologists.
In addition to this reguarally updated content, sections detailing the diagnosis, treatment and monitoring of men with erectile dysfunction (ED) or hypogonadism (low testosterone) are also available. This extensive resource aims to provide endocrinologists and other healthcare professionals with a better understanding of the epidemiology and etiology of these diseases and provide information about available treatment options for these men.
The emphasis in these Guidelines is to provide information on the current state of the art in how to..
... prevent and manage the diverse problems associated with
the effects of DM (Diabetes Mellitus) on the heart and vasculature in a holistic manner. In describing the mechanisms of disease,we hope to provide an educational tool and, in describing the latest management approaches, an algorithm for achieving the best care for patients in an individualized setting. It should be noted that these guidelines are written for the management of the combination of CVD (or risk of CVD) and DM, not as a separate guideline for each condition.
The consequences of Subclinical Hypothyroidism (SCH) are variable at several levels and may depend..
... on the duration and the degree of elevation of the serum TSH. However, a number of important questions about SCH remain, including whether it increases cardiovascular (CV) risk or mortality, whether it negatively influences metabolic parameters and whether it should be treated with L -thyroxine.
These open questions have prompted the European Thyroid Association (ETA) to form a task force with the aim of drawing up guidelines on the management of SCH in adults. A specific guideline on the management of SCH in children and in pregnancy will be prepared separately and these subjects are not covered in this guidance. Similarly, interpretation of elevated serum TSH while taking amiodarone is not covered in this guideline. Population screening for hypothyroidism was also considered a separate issue and is not covered by this guideline.
The objectives of this project are to test whether alteration in DNA hypermethylation in plasma is:
- a diagnostic marker for pancreatic cancer
- a prognostic marker for pancreatic cancer
- a marker for recurrence of pancreatic cancer
- changing during the course of chronic pancreatitis, with the purpose of..
... finding patients with high risk of developing pancreatic cancer
This observational study is aimed at assessing insulin secretion and sensitivity by the use of a mathematical modeling from oral glucose tolerance test in subjects with liver cirrhosis undergoing orthotopic liver transplantation (OLT), before and at various time points after OLT.